Eva Fernández

Instituto Cajal

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

S. Sancho

Instituto Cajal

A. Hervás

Hospital Universitario Ramón y Cajal

R. Hernánz

Instituto Cajal

Arturo Navarro‐Martin

Institut Català d'Oncologia

Marina Alarza

Instituto Cajal

Carolina de la Pinta

Hospital Universitario Ramón y Cajal

Carmen Vallejo

Hospital Universitari de Girona Doctor Josep Trueta

Teresa Muñóz

Hospital Universitario Ramón y Cajal

M Del Campo Martín

Instituto Cajal

Paula Jiménez‐Fonseca

Central University Hospital of Asturias

Cooperative Institutions

Fundación Kovacs

Instituto Cajal

Instituto Ramón y Cajal de Investigación Sanitaria

Hospital Universitario Ramón y Cajal

Institut Català d'Oncologia

Centro de Investigación Biomédica en Red

Hospital Universitario de Valme

Universitat de Barcelona

Instituto de Salud Carlos III

Institut d'Investigació Biomédica de Bellvitge

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Spine Instability Neoplastic Score: agreement across different medical and surgical specialties

The Spine Journal (2015)

Estanislao Arana Francisco M. Kovacs Ana Royuela Beatriz Asenjo Úrsula Pérez‐Ramírez

Cohen's kappa

Specialty

Kappa

10.1016/j.spinee.2015.10.006

Cite

Citations (57)

SARS-CoV-2 Virus in Cancer Patients: A New Unknown in an Unsolved Equation

Oncology (2022)

M. Martín Carmen Vallejo Fernando López‐Campos Carmen Quereda Teresa Muñóz

Introduction: Cancer patients are more susceptible to infections, and infection can be more severe than in patients without cancer diagnosis. We conducted this retrospective study in patients admitted for SARS-CoV-2 infection in order to find differences in inflammatory markers and mortality in cancer patients compared to others. Methods: We reviewed the electronic records of patients admitted for SARS-CoV-2 infection confirmed by PCR from March to September 2020. Data on socio-demographics, comorbidities, inflammatory makers, and cancer-related features were analyzed. Results: 2,772 patients were admitted for SARS-CoV-2, to the Hospital Universitario Ramón y Cajal in Madrid during this period. Of these, 2,527 (91%) had no history of neoplastic disease, 164 (5.9%) patients had a prior history of cancer but were not undergoing oncological treatment at the time of infection, and 81 (2.9%) were in active treatment. Mortality in patients without a history of cancer was 19.5%, 28.6% for patients with a prior history of cancer, and 34% in patients with active cancer treatment. Patients in active oncology treatment with the highest mortality rate were those diagnosed with lung cancer (OR 5.6 95% CI: 2.2–14.1). In the multivariate study, active oncological treatment (OR 2.259 95% CI: 1.35–3.77) and chemotherapy treatment (OR 3.624 95% CI: 1.17–11.17), were statistically significant factors for the risk of death for the whole group and for the group with active oncological treatment, respectively. Conclusion: Cancer patients on active systemic treatment have an increased risk of mortality after SARS-CoV-2 infection, especially with lung cancer or chemotherapy treatment.

10.1159/000525802

Cite

Citations (0)

Abstract A9: Chronology of arterial hypertension and microalbuminuria associated with inhibiting treatments of vascular endothelium growth factor receptor in patients with cancer.

Molecular Cancer Therapeutics (2011)

José Fuentes Pradera J. Salvador Antonio Grilo Maria M. Rodríguez Amelia Ramón López

Abstract Purpose: Angiogenesis plays a major role in cancer. Drugs blocking the growth factor receptor in the vascular endothelium constitute a fundamental treatment in several cancers. Hypertension (HBP) and proteinuria associated with these treatments is frequent and presents in an oscillating and irregular way and is generally controlled by scarcely reliable means. Methods: We started a prospective study with the determination of microalbuminuria (MAL) in 24 hours orine samples and the execution of pre- and post-treatment 24 h-ambulatory blood pressure monitoring (ABPM) and selfmeasured of BP every 12 hours at home, during 60 days, in patients with cancer under treatment with either bevacizumab or sunitinib with a view to identifying the variations in MAL, ABPM and the onset of HBP at an early stage. For ABPM, a validated recording device was used; a recording was made prior to the start of the anti-angiogenic treatment and 20 days (at least) after the first dose. An OMRON M6 tensiometer validated by the European HBP Society was used, with the ambulatory BP figures being collected at home as per standards. MAL was measured in 24h orine samples in mg/L and mg/gr creatinine. The primary goal is to find differences of at least 16 mmHg in the mean BP between the two ABPM readings. Results: N=21. Eighteen patients received bevacizumab and three sunitinib. Mean age 57.0 years (26–79). Three patients was known to be hypertensive. Differences of 4.9 and 3.9 mmHg were found between the mean systolic and diastolic BPs before and after treatment (p<0.05). Conclusions: Our data revealed a statically significant increase of blood pressure in patients treated with antiangiongenics as determined by ABMP. The data point to a greater increase in nocturnal BP suggesting a non-dipper pattern. The self measured records shown an early onset HBP. Microalbuminuria trends to increase in this patients. All data will be shown at the meeting. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A9.

Microalbuminuria

10.1158/1535-7163.targ-11-a9

Cite

Citations (0)

NEOHX study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER-2 resectable stomach or esophagogastric junction (EGJ) adenocarcinoma—18 m DFS analysis.

Journal of Clinical Oncology (2015)

Fernando Rivera Paula Jiménez‐Fonseca Pilar Alfonso Javier Gállego María Luisa Limón

107 Background: Perioperative chemotherapy has demonstrated better OS and DFS than surgery alone in resectable stomach or EGJ adenocarcinoma. Trastuzumab has improved OS when added to chemotherapy in pts with HER-2 + metastatic gastric cancer and is interesting to explore its role in the perioperative setting. Methods: A Spanish, multicenter, open-label phase II study evaluated the efficacy and toxicity profile of perioperative XELOX-T (Capecitabine 1000 mg/m2/12h po days 1-14, oxaliplatin 130 mg/m2 day 1, trastuzumab 8 mg/kgà6 mg/kg day 1, q3w ; 3 preoperative cycles and 3 postsurgery cycles followed by 12 cycles of trastuzumab monotherapy) in patients with T1-2N+M0 or T3-4NxM0 resectable stomach or EGJ adenocarcinoma, HER-2+ ( IHQ3+ or IHQ2+/FISH+). The primary endpoint was 18 months DFS, secondary endpoint included pCR, R0 resection rate, ORR, toxicity of preoperative treatment (NCI CTC v3.0 criteria) and biomarker analysis. Results: From June 2010 to March 2012, 36 pts were included: median age 65 (39-85); ECOG 0/1/2: 16/19/1 pts; localization: stomach 21 pts, EGJ 15 pts; histologic type: intestinal: 23 pts, diffuse: 4 pts, mixed: 1pt, not specified 8 pts; TNM: T 4: 7 pts; N+: 31 pts. Preoperative XELOX-T: Response: PR: 14 pts (39%), SD: 18 pts, PD: 0 pts, NE: 4 pts. Surgery was performed in 31 pts: R0: 28 pts (78%, 95% CI: 61-90%), R1: 1 pt, R2: 2 pts (1 had peritoneal carcinomatosis); pCR was observed in 3 pts (8.3 %; 95% CI: 2-22%). Two pts died due to surgical complications. After R0/R1 resection, postoperative XELOX-T was administered to 24 patients, 22 of whom underwent T monotherapy. G3-4 toxicity (>5% of pts): diarrhea 33%, nauseas and vomiting 8% and pneumonia, anemia, neutropenia, anorexia, asthenia and pleural effusion with pneumothorax: 5.5%. With a median follow up of 24.1 months, 18m DFS is 71% (95% CI: 53-83%), 24 m DFS is 60% and median DFS and OS has not been reached. Conclusions: These data suggest that perioperative XELOX+T in HER-2 positive resectable stomach or esophagogastric junction adenocarcinoma is feasible and has promising activity. Clinical trial information: NCT01130337.

Clinical endpoint

Epirubicin

10.1200/jco.2015.33.3_suppl.107

Cite

Citations (23)

1840: Validation of the METABANK score in oligometastatic patients after SBRT in a tertiary care center.

Radiotherapy and Oncology (2024)

Marta Camacho Manzanares J. M. Azcona M. Centelles Francisco Mesa Carolina de la Pinta

Tertiary care

Center (category theory)

10.1016/s0167-8140(24)02161-3

Cite

Citations (0)

W03-P-010 Insulin resistance and endothelial dysfunction in hypertensive patients

Atherosclerosis Supplements (2005)

Óscar Infante E. Sanchez-Largo Eva Fernández E. Benal B MONGE

Endothelial Dysfunction

10.1016/s1567-5688(05)80057-1

Cite

Citations (0)

Agreement in the assessment of metastatic spine disease using scoring systems

Radiotherapy and Oncology (2015)

Estanislao Arana Francisco M. Kovacs Ana Royuela Beatriz Asenjo Úrsula Pérez‐Ramírez

Specialty

Radiation oncology

Cohen's kappa

10.1016/j.radonc.2015.03.016

Cite

Citations (14)

Lung ultrasound in acute myocardial infarction. Updating Killip & Kimball

Indian Heart Journal (2020)

Jorge Parras Mariela Onocko Liliana M. Traviesa Eva Fernández Pablo M. Morel

Heart failure complicating acute myocardial infarction marks an ominous prognosis. Killip and Kimball's classification of heart failure remains a useful tool in these patients. Lung ultrasound can detect pulmonary congestion but its usefulness in this scenario is unknown. To investigate the diagnostic accuracy of lung ultrasound to predict heart failure in patients with acute myocardial infarction. Patients admitted with acute myocardial infarction and without heart failure were evaluated with a lung ultrasound. The presence of B-lines was recorded and counted. The presence of new heart failure (Killip Class B, C, or D) during hospitalization was evaluated by a cardiologist blinded to the results of lung ultrasound. A ROC curve analysis was done to evaluate the diagnostic accuracy of B-lines to predict heart failure. 200 patients were included. Three patients were diagnosed with cardiogenic shock, 5 with acute pulmonary edema, and 17 with mild heart failure. Patients who develop heart failure had a median of 14 B-lines, however, patients who remained in Killip class A had a median of 2 (p = 0,0001). The area under the ROC curve of the sum of B-lines to predict any form of heart failure was 0,91 (CI95% 86–97). The best cut-off value was 5 B-lines, with a sensitivity of 88% (IC95% 68,8–97,5) and specificity of 81% (IC95% 73,9–86,2). Lung ultrasound done at admission can help to predict heart failure In patients with acute myocardial infarction.

Killip class

10.1016/j.ihj.2020.11.148

Cite

Citations (8)

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

European Journal of Cancer (2021)

Fernando Rivera Marta Izquierdo-Manuel Pilar García‐Alfonso Eva Martínez de Castro Javier Gállego

Clinical endpoint

10.1016/j.ejca.2020.12.005

Cite

Citations (42)

Recurrent Glioblastoma: A Review of the Treatment Options

Cancers (2023)

Maria Angeles Vaz-Salgado María Villamayor Víctor Albarrán V. Navarro Pilar Sotoca

Glioblastoma is a disease with a poor prognosis. Multiple efforts have been made to improve the long-term outcome, but the 5-year survival rate is still 5-10%. Recurrence of the disease is the usual way of progression. In this situation, there is no standard treatment. Different treatment options can be considered. Among them would be reoperation or reirradiation. There are different studies that have assessed the impact on survival and the selection of patients who may benefit most from these strategies. Chemotherapy treatments have also been considered in several studies, mainly with alkylating agents, with data mostly from phase II studies. On the other hand, multiple studies have been carried out with target-directed treatments. Bevacizumab, a monoclonal antibody with anti-angiogenic activity, has demonstrated activity in several studies, and the FDA has approved it for this indication. Several other TKI drugs have been evaluated in this setting, but no clear benefit has been demonstrated. Immunotherapy treatments have been shown to be effective in other types of tumors, and several studies have evaluated their efficacy in this disease, both immune checkpoint inhibitors, oncolytic viruses, and vaccines. This paper reviews data from different studies that have evaluated the efficacy of different forms of relapsed glioblastoma.

10.3390/cancers15174279

Cite

Citations (37)